SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the approaching FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the companys amended application and longer-term upper-limb data alongside recent FDA discussion of flexibility in rare-disease reviews. Many are bullish and read commercial hiring as a sign of launch preparation, while skeptics stress that approval is uncertain given the earlier negative review and debate over the evidence; some also cite Inovios separate FDA approval as a positive sentiment signal.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is climbing toward a 52-week high as traders position for anticipated Q3 results, with BRIUMVIs sales growth adding to optimism. Buyout and short-squeeze theories are circulating, but the acquisition talk is unconfirmed, and some traders question whether earnings expectations are already reflected in the run-up.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about new competition for Precigens PAPZIMEOS. Traders debate the threat: some see a serious challenge, while others argue Precigen retains an advantage from its commercial head start and full approval, and view the selloff as an overreaction.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Traders are discussing Oktas reported addition to the S&P 500 in place of KVUE, with some anticipating index-related buying and others warning of a sell-the-news reaction. Separately, claims of a DHS data exposure involving Oktas login system are adding bearish concern, though those claims are not established in the discussion.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

MLYS is under pressure amid concerns that the slow early commercial ramp for AstraZenecas competing hypertension drug could signal a challenging launch and weaker near-term sales prospects for lorundrostat. Traders disagree on whether that undermines Mineralyss commercial outlook, with some emphasizing the upcoming FDA decision and clinical data while others question its ability to compete independently.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported major Binance security breach, with withdrawals temporarily suspended and billions in crypto reportedly affected, is driving attention to BNB and broader crypto-market concerns. Traders are debating whether the incident threatens trust in Binance and warrants further selling, while others view the selloff as an overreaction; claims of an inside job remain speculation.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is being discussed amid volatile crude prices and shifting Middle East supply risks, especially tensions and shipping disruptions around the Strait of Hormuz. Traders debate why PR often fails to track oils moves, while some point to the companys production growth, guidance and dividends as support for a longer-term bullish view.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is the dominant topic, with traders citing share dilution and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to its strategic U.S. HALEU supply role and government contracts as long-term support, while others question the valuation and whether the decline has further to run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results PR Newswire PRINCETON, N.J., Aug. 7, 2026 PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc.(Nasdaq: SNGX) (Soligenix or the Company...

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine PR Newswire PRINCETON, N.J., June 8, 2026 Thermostability, immunogenicity and efficacy data against related viruses provides firm starting...

These Stocks Are Dominating the Power Hour into the Close

Today’s trading session saw aggressive momentum rotate back into speculative growth, biotech, AI infrastructure, and emerging technology names as traders hunted for high-volatility opportunities heading into the closing bell and after-hours session. Several low-float biotech and technology stocks experienced sharp increases in volume following clinical updates, financing announcements, analyst attention, and broader retail speculation. $NTHI, $QBTT, $ASTI, $MNTS, $APPS, $SNGX, $AMSS

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

Equity

Soligenix shares are also poised to break above the 100-day moving average for the first time in a month, following a four-session rally.

Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus

Soligenix shares surged 72.32% in after-hours trading following rapid Bundibugyo virus vaccine development announcement.read more...

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo PR Newswire PRINCETON, N.J., May 26, 2026 Thermostability, immunogenicity and efficacy data against related...

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results Soligenix Announces Recent Updates and First Quarter 2026 Financial Results PR Newswire PRINCETON, N.J., May 8, 2026...

LCID, SNGX, SRAD Stock Hit 52-Week Lows Today: What's Driving The Selloff? 

On Tuesday, LCID stock slipped 1%, marking its fifth straight session of losses, while SNGX plunged 70% and SRAD fell 11%.

SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment

An independent committee recommended stopping Soligenix’s late-stage trial to treat lymphoma due to a lack of effectiveness.

Why Is Soligenix Stock Sinking Tuesday?

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.read more...

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Soligenix Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Soligenix said its thermostable platform can quickly advance the development of a single-vial Bundibugyo virus vaccine.</li><li>The company has developed the platform in partnership with the University of Hawai’i</li><li>Short interest in the stock is at a six-month high, according to Koyfin data.</li></ul>Shares of Soligenix (SNGX) surged more than 110% in Wednesday’s pre-market session, putting the biotech stock on pace to reclaim the crucial $1 level for the first time in a month after investors rushed in on optimism surrounding potential vaccine development efforts tied to the latest Ebola outbreak.<a href="https://stocktwits.com/symbol/SNGX">SNGX shares</a> are poised to break above the key 100-day moving average for the first time in a month, and could extend a four-session rally that has lifted the stock more than 34%.Short interest in the stock is at a six-month high, according to Koyfin data.<h2 class="st-heading-2">SNGX, Hawai’i University Tie Up</h2>On Tuesday, Soligenix said it has developed thermostable vaccine formulations in partnership with the University of Hawaii that can be stored and shipped more easily in regions affected by the virus.It added that, with enough funding, it could quickly advance development of a single-vial Bundibugyo virus vaccine that may simplify global vaccination and booster efforts.“A single-vial subunit vaccine that can be shipped at ambient temperatures and then needs to only be reconstituted with sterile water immediately prior to use has the potential to improve vaccination efforts globally by simplifying storage and distribution logistics not only as a stand-alone vaccine, but also as a practical add-on booster in persons previously vaccinated with other vaccines,” said Axel Lehrer, a professor at the university.“Given adequate funding, we are confident we could rapidly advance development of a thermostable Bundibugyo virus vaccine, individually or in combination with vaccines developed previously.”<h2 class="st-heading-2">Over 220 Suspected Deaths From Ebola</h2>Health officials have been scrambling to contain the spread of the Ebola outbreak in the Democratic Republic of Congo and Uganda, with authorities ramping up monitoring efforts following the emergence of new infections in the region.The Centers for Disease Control and Prevention has also called for tighter screening measures for travelers arriving from affected countries.Earlier this month, the World Health Organization (WHO) classified the outbreak as a public health emergency of international concern. The agency said the outbreak has resulted in more than 900 suspected infections and 223 suspected deaths.<h2 class="st-heading-2">What Is Retail’s Take On SNGX?</h2>The stock has generated significant retail interest, with sentiment on Stocktwits turning ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter on the counter increased by nearly 14,000% over a 7-day period.One user saw resistance between $1.13 and $1.15.<stembedurl>https://stocktwits.com/Daniel_2025/message/654462945</stembedurl>Another user highlighted the company’s strong pipeline.<stembedurl>https://stocktwits.com/durocali/message/654440033</stembedurl>The stock has been under heavy selling pressure so far this year, declining more than 63%.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/crypto-extreme-fear-returns-with-bitcoin-at-75-k/cZgg4iZReAp">Crypto ‘Extreme Fear’ Returns With Bitcoin At $75K – Retail Traders Say BTC Bulls Missed The Tech Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month On Ebola Vaccine Optimism

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.3559
Prev Close	$0.3693
Open	$0.3776
Dividend Yield	0.00%
50-Day Moving Average	$0.3685
Beta	1.25
Avg. Volume	229,660.37
PE Ratio	-0.29

52-Week High	$1.70
52-Week Low	$0.28
Market Capitalization	$8.04M
EPS (Annual)	-$2.14
Price to Book	1.20
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

SNGX Fundamentals